Progressive Muscle Relaxation and Cigarette Craving

May 31, 2014 updated by: Rasmon Kalayasiri, Chulalongkorn University

Preliminary Study of Effects of Progressive Muscle Relaxation on Cigarette Craving and Withdrawal Symptoms of Experienced Smokers in Acute Cigarette Abstinence : A Randomised Control Trial

Cigarette craving usually occurs with unpleasant feelings, including stress. Progressive Muscle Relaxation (PMR) may reduce level of cigarette craving and/or withdrawal symptoms.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The study reports on a study investigating the acute effects of a one-time application of progressive muscle relaxation on craving for cigarettes in smokers who were instructed to abstain from cigarettes for 3 hours.

Study Type

Interventional

Enrollment (Actual)

34

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Thailand
      • Bangkok, Thailand, 10330
        • Department of Psychiatry, Faculty of Medicine, Chulalongkorn University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 18 years or more
  • Daily cigarette smokers

Exclusion Criteria:

  • Hospitalization
  • Participating in cigarette dependency treatment or trying to quit smoking with other methods
  • Uncontrolled blood pressure
  • Current other substance users (except alcohol)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Progressive muscle relaxation
Progressive muscle relaxation: single 20-minutes session
Behavioral: Progressive Muscle Relaxation
Comparison of progressive muscle relaxation and no intervention (e.g., reading newspaper of the day) for the same amount of time.
No Intervention: Reading newspaper of the day
Reading newspaper of the day : single 20-minutes session

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Craving
Time Frame: Immediately after a 20-minutes session of progressive muscle relaxation
Craving, a strong desire for using a substance when abstaining from substance, was measured by the Penn Alcohol Rating Scale - adapted (PACS-adapted) and the Visual Analog Scale (VAS).
Immediately after a 20-minutes session of progressive muscle relaxation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cigarette withdrawal-related and non-withdrawal related feelings
Time Frame: Immediately after a 20-minutes session of progressive muscle relaxation
Cigarette withdrawal symptoms (i.e., anxious, hungry, feeling bad, restless) and non-withdrawal (i.e., high, stimulated, paranoid, tongue - tied) (59-61), as measured by using the Visual Analog Scale (VAS)
Immediately after a 20-minutes session of progressive muscle relaxation

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood pressure
Time Frame: Immediately after a 20-minutes session of progressive muscle relaxation
Systolic and diastolic blood pressure, measured by an automated machine
Immediately after a 20-minutes session of progressive muscle relaxation
Pulse rate
Time Frame: Immediately after a 20-minutes session of progressive muscle relaxation
Pulse rate, measured by an automated machine
Immediately after a 20-minutes session of progressive muscle relaxation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Chulalongkorn University

Investigators

  • Principal Investigator: Thatsanee Limsanon, M.Sc., Chulalongkorn University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2012

Primary Completion (Actual)

November 1, 2012

Study Completion (Actual)

November 1, 2012

Study Registration Dates

First Submitted

May 26, 2014

First Submitted That Met QC Criteria

May 31, 2014

First Posted (Estimate)

June 3, 2014

Study Record Updates

Last Update Posted (Estimate)

June 3, 2014

Last Update Submitted That Met QC Criteria

May 31, 2014

Last Verified

May 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRB031/55

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe